兆科眼科-B(06622.HK)與Visus達成獨家許可協議
格隆匯5月11日丨兆科眼科-B(06622.HK)發佈公吿,公司與Visus Therapeutics, Inc.達成獨家許可協議,以於大中華區、南韓及指定東南亞地區開發及商業化BRIMOCHOLTM PF及Carbachol PF。Visus為處於臨牀階段的製藥公司,專注於開發創新眼科療法,以改善世界各地民眾視力。BRIMOCHOLTM PF及Carbachol PF乃不含防腐劑的新藥,將為矯正因老花眼而喪失的近距離視力的長效一日一次滴眼液。
根據該協議的條款,公司將負責BRIMOCHOLTM PF及Carbachol PF在指定地區的臨牀開發及監管審批,然後進行該等產品的商業化活動。公司將支付預付款1500萬美元,其後可能於各個監管、商業化及銷售里程碑支付最多1.15億美元。公司將利用Visus用於現時招募中的第3期研究的精深臨牀開發經驗與計劃,迅速達成所需臨牀規定並推出產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.